关于业务拓展，公司从服务终端业务内容和规模拓展两方面推动建设。业务内容上，除近视防控和硬镜 产品，拓展其他功能性视力矫正产品、干眼和视疲劳、视觉功能训练等业务。规模扩大方面，侧重新建 有用户资源的视光终端，以及投资收购成熟视光服务机构。 销售部门方面，公司持续充实调整优化，如在各区域增加技术支持和销售辅助人员，成立第二经销中心 负责硬镜外视光产品销售，组建并扩大线上销售团队。 校企合作与产能规划 欧普康视于2025年9月2日举办了2025年半年度报告网上说明会，线上全体投资者参与此次业绩说明会， 公司创始人、董事长兼总经理陶悦群博士等多位高层出席，就公司多项业务发展情况与投资者展开交 流。 投资者关系活动关键信息投资者活动关系类别：业绩说明会时间：2025年9月2日15:30 - 16:30地点：价 值在线（https://www.ir-online.cn/）网络互动参与单位名称：线上参与欧普康视（300595）2025年半年 度报告网上说明会的全体投资者上市公司接待人员姓名：创始人、董事长兼总经理陶悦群博士；董事、 副总经理兼董事会秘书施贤梅女士；董事、财务总监卫立治先生；独立董事许立新 业务发展情况披露 ...

证券代码：300595 证券简称：欧普康视 欧普康视科技股份有限公司 2025 年 9 月 2 日投资者关系活动记录表 Q3：虽然有市场环境的外因在，内因也是影响业绩的重要一环，是否 在考虑对销售部门做出调整？ A：您好，公司一直在对业务部门进行充实调整优化。比如，公司在 各个区域都增加了技术支持人员和销售辅助人员。公司成立了第二经销中 心负责硬镜以外视光产品的销售。公司组建并不断扩大线上销售团队的规 模等。公司将根据市场的变化和需要继续调整和升级销售队伍。感谢您的 建议！ 编号：2025-006 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 □现场参观 □在线会议 参与单位人 员情况 线上参与欧普康视（300595）2025 年半年度报告网上说明会的全体投资者 时 间 2025 年 9 月 2 日 15:30-16:30 地 点 价值在线（https://www.ir-online.cn/）网络互动 上市公司参 会人员 创始人、董事长兼总经理 陶悦群博士 董事、副总经理兼董事会秘书 施贤梅女士 董事、财务总监 卫立治先生 独立董事 许立新 投资者关系 ...

Policy Developments - Shanghai is advancing the standardization research of medical accompaniment services, with a project led by East China Hospital identified as a key research topic for 2024, focusing on service institutions, personnel requirements, service processes, and quality evaluation [2] Drug and Device Approvals - Maike Bio has received a medical device registration certificate for its coagulation factor activity measurement kits, valid from July 8, 2025, to July 7, 2030, aimed at monitoring treatments for coagulation factor deficiencies [3] - Kewang Pharmaceutical's vitamin K1 drops have received a registration acceptance notice from the National Medical Products Administration, intended to prevent vitamin K deficiency bleeding in infants [4] - CanSino has been approved for clinical trials of its trivalent poliovirus vaccine, which is being developed using protein structure design and VLP assembly technology, currently undergoing I/II phase trials in Indonesia [5] Financial Reports - Johnson & Johnson reported Q2 revenue of $23.74 billion, a 5.8% increase year-over-year, exceeding market expectations, with projected annual sales between $93.2 billion and $93.6 billion [6] Capital Markets - Tuoxin Pharmaceutical plans to invest 10 million yuan in Jiangsu Jinsan Biotechnology Co., acquiring a 1.75% stake, with Jinsan successfully producing high-purity ergothioneine for various products [7] - Tsinghua Unigroup's stock auction resulted in the sale of 58.607 million shares, potentially leading to a change in control of the company, with the shares sold at an average price significantly above the latest closing price [8] Industry Events - China National Pharmaceutical Group responded to rumors regarding the "return" of a licensing agreement with Merck for a PD-1/VEGF bispecific antibody, stating that the collaboration is progressing normally and a milestone payment of $300 million is expected upon completion of technology transfer by 2025 [9] Public Sentiment Alerts - A senior executive of Astellas Pharma in China was sentenced to three and a half years in prison for espionage, highlighting potential risks in the pharmaceutical industry [10] Stock Market Alerts - ST Weiming's stock has been placed under risk warning due to a significant price drop and expected losses of 55 million to 85 million yuan for the first half of 2025, leading to a change in its trading name and restrictions on price fluctuations [11]

Core Viewpoint - Toxin Pharmaceutical (301089.SZ) plans to invest 10 million yuan in Jiangsu Jiansan Biotechnology Co., Ltd. (referred to as "Jiansan Biotechnology") to acquire a 1.75% stake in the company, which has successfully developed high-purity ergothioneine [1] Group 1 - Toxin Pharmaceutical will use its own funds for the investment of 10 million yuan [1] - After the investment, Toxin Pharmaceutical will directly hold 1.75% of Jiansan Biotechnology's equity [1] - Jiansan Biotechnology has achieved the production of high-purity ergothioneine, with main products including ergothioneine skincare products, oral capsules, and eye wash solutions [1]